This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Related letter  • Similar articles in JAMA  Topic Collections  • Transplantation  • Transplantation, Other  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: As emphasized by Dr Koreth and colleagues,¹ the assessment of allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission requires controlled prospective clinical trials. In their meta-analysis, the authors evaluated trials in which treatment assignment was based on the presence or absence of an HLA-matched donor. Although the authors recognized the inclusion of patients having no siblings as a source of bias,² they did not select their group for analysis accordingly.

Of the patients in their meta-analysis, 91% were from published trials of donor vs no-donor analyses, in which patients without siblings were included in the no-donor group. Reliable data on the relative value of allogeneic stem cell transplantation for acute myeloid leukemia in the past requires re-evaluation of donor vs no-donor comparisons focused on documented tissue-typed patients and their siblings.

Concerns about the equivalence of related and unrelated donors should no longer be . . . [Full Text of this Article]

Thomas Büchner, MD
buechnr@uni-muenster.de
Department of Hematology and Oncology
University of Münster
Münster, Germany

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: Systematic Review and Meta-analysis of Prospective Clinical Trials
John Koreth, Richard Schlenk, Kenneth J. Kopecky, Sumihisa Honda, Jorge Sierra, Benjamin J. Djulbegovic, Martha Wadleigh, Daniel J. DeAngelo, Richard M. Stone, Hisashi Sakamaki, Frederick R. Appelbaum, Hartmut Döhner, Joseph H. Antin, Robert J. Soiffer, and Corey Cutler
JAMA. 2009;301(22):2349-2361.
ABSTRACT | FULL TEXT  

RELATED LETTER

Donor Availability and Clinical Trials for Allogeneic Stem Cell Transplantation—Reply
John Koreth and Corey S. Cutler
JAMA. 2009;302(15):1647-1648.
EXTRACT | FULL TEXT